IDEXX Laboratories (IDXX) is Reiterated by Stifel to Buy, Raises Price Target to $ 125

IDEXX Laboratories (IDXX) was Reiterated by Stifel to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 125 from a previous price target of $120 . Stifel advised their investors in a research report released on Aug 16, 2016.

Many Wall Street Analysts have commented on IDEXX Laboratories. IDEXX Laboratories was Upgraded by Northcoast to ” Neutral” on Aug 3, 2016. Company shares were Reiterated by Canaccord Genuity on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 98 from a previous price target of $90 .

On the company’s financial health, IDEXX Laboratories reported $0.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $466.56 million for the quarter, compared to analysts expectations of $445.57 million. The company’s revenue was up 12.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.60 EPS.

IDEXX Laboratories opened for trading at $111.48 and hit $112.26 on the upside on Monday, eventually ending the session at $111.92, with a gain of 1.03% or 1.14 points. The heightened volatility saw the trading volume jump to 4,30,940 shares. Company has a market cap of $10,021 M.

In a different news, on Aug 9, 2016, Michael J Phd Williams (Executive Vice President) sold 49,560 shares at $108.94 per share price. According to the SEC, on Aug 5, 2016, William T End (director) sold 5,000 shares at $108.50 per share price. On Aug 4, 2016, Jonathan W Ayers (Chairman, President & CEO) sold 60,000 shares at $107.88 per share price, according to the Form-4 filing with the securities and exchange commission.

IDEXX Laboratories Inc. develops manufactures and distributes products and provides services primarily for the companion animal veterinary livestock and poultry water testing and dairy markets. The Company sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include Companion Animal Group (CAG) Water Livestock Poultry and Dairy and Other. Its Products and services include point-of-care veterinary diagnostic products; veterinary reference laboratory diagnostic and consulting services; practice management systems and services and digital imaging systems; biological materials testing laboratory animal diagnostic instruments and services; diagnostic health-monitoring and food safety testing products for livestock poultry and dairy; products that test water for microbiological contaminants and point-of-care electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

IDEXX Laboratories

Leave a Reply

IDEXX Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on IDEXX Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.